Mycophenolic Acid
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Mycophenolic Acid: From Transplant Immunosuppression to Hemoglobinopathy
One-Sentence Summary
Mycophenolic acid is an immunosuppressant that blocks lymphocyte proliferation. It is marketed in Singapore as gastro-resistant or delayed-release tablets, but the data compiled for this report do not include an approved indication text. The TxGNN model predicts it may be effective for hemoglobinopathy, with 1 indirectly related clinical trial and 1 directly related publication (a pediatric thalassemia dosing study) currently supporting this direction. The evidence is weak and mostly indirect, so this is best treated as a research question rather than a ready-to-use new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.60% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the drug record. From the literature compiled for this report, mycophenolic acid is known to inhibit inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for guanine nucleotide synthesis. This suppresses the proliferation of T and B lymphocytes. Its prodrug, mycophenolate mofetil, is widely used to prevent rejection after organ transplantation.
In hemoglobinopathies such as thalassemia, mycophenolic acid is not expected to correct the underlying globin chain imbalance. Its plausible role is in the allogeneic hematopoietic stem cell transplant (HSCT) setting, where it is used to prevent graft-versus-host disease (GVHD), and possibly for immune-mediated complications. A 2025 pediatric study of mycophenolate mofetil dosing in thalassemia patients undergoing HSCT suggests this off-label use is already being considered clinically.
The high TxGNN score is therefore best read as reflecting the transplant-related link, not a disease-modifying effect. The other predicted conditions (for example, migraine, chromosomal deletion syndromes and red cell enzyme defects) have no identified mechanistic link and no supporting evidence. Rheumatoid arthritis, which ranks ninth, has biologically plausible but dated evidence only.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02342145 | Phase 4 | Completed | 205 | Basiliximab for preventing acute GVHD in unrelated allogeneic stem cell transplantation for thalassemia major. It does not test mycophenolic acid directly, so relevance is indirect. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39891881 | 2025 | Dosing / population pharmacokinetic study | Eur J Drug Metab Pharmacokinet | Population PK model and simulated dosing for off-label mycophenolate mofetil GVHD prevention in pediatric thalassemia patients undergoing HSCT |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12377P | Myfortic Gastro-Resistant Tablet 360 mg | Tablet, film coated | Not stated in the data |
| SIN12376P | Myfortic Gastro-Resistant Tablet 180 mg | Enteric coated tablet | Not stated in the data |
| SIN16638P | Murest-DR 180 Delayed-Release Tablets 180 mg | Tablet, delayed release | Not stated in the data |
| SIN16637P | Murest-DR 360 Delayed-Release Tablets 360 mg | Tablet, delayed release | Not stated in the data |
| SIN16970P | Mofecon-GR 360 Gastro-Resistant Tablets 360 mg | Tablet, enteric coated | Not stated in the data |
One further registration, SIN16969P (Mofecon-GR 180), is also valid. All 6 registrations are single-ingredient oral products.
Safety Considerations
Drug Interactions: The interaction screen returned 100 interacting drugs. The entries reviewed here, mostly rated Moderate, include:
- Major: activated charcoal
- Moderate: antibiotics (doxycycline, amoxicillin, clarithromycin, minocycline, tetracycline, vancomycin, kanamycin, paromomycin, levofloxacin, metronidazole) and antacids or mineral products (magnesium oxide, magnesium hydroxide, magnesium carbonate, aluminum hydroxide, magaldrate, calcium carbonate)
- Minor: zinc sulfate, zinc acetate, iron
Antacids and minerals may reduce absorption of the drug. Other considerations are the effects of antibiotics on gut flora and drug exposure, and the infection risk that comes with immunosuppression.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction score is high, but the supporting evidence is indirect: one trial tests a different drug and one pharmacokinetic dosing study covers a transplant setting. No efficacy trial of mycophenolic acid in hemoglobinopathy is available, and the mechanism does not address the core disease.
- Safety label information is also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- The Singapore package insert, to confirm approved indications, warnings and contraindications
- Mechanism of action data from DrugBank
- Prospective or comparative clinical data on mycophenolate in thalassemia or sickle cell disease, particularly GVHD prophylaxis in HSCT
- A decision on whether the question should be reframed as transplant-related GVHD prophylaxis rather than hemoglobinopathy treatment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.